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Abstract
Background: A low cerebrospinal fluid (CSF) white-blood cell count (WBC) has been identified
as an independent risk factor for adverse outcome in adults with bacterial meningitis. Whereas a
low CSF WBC indicates the presence of sepsis with early meningitis in patients with meningococcal
infections, the relation between CSF WBC and outcome in patients with pneumococcal meningitis
is not understood.
Methods: We examined the relation between CSF WBC, bacteraemia and sepsis in a prospective
cohort study that included 352 episodes of pneumococcal meningitis, confirmed by CSF culture,
occurring in patients aged >16 years.
Results: CSF WBC was recorded in 320 of 352 episodes (91%). Median CSF WBC was 2530 per
mm3 (interquartile range 531–6983 per mm3) and 104 patients (33%) had a CSF WBC <1000/mm3.
Patients with a CSF WBC <1000/mm3 were more likely to have an unfavourable outcome (defined
as a Glasgow Outcome Scale score of 1–4) than those with a higher WBC (74 of 104 [71%] vs. 87
of 216 [43%]; P < 0.001). CSF WBC was significantly associated with blood WBC (Spearman's test
0.29), CSF protein level (0.20), thrombocyte count (0.21), erythrocyte sedimentation rate (-0.15),
and C-reactive protein levels (-0.18). Patients with a CSF WBC <1000/mm3 more often had a
positive blood culture (72 of 84 [86%] vs. 138 of 196 [70%]; P = 0.01) and more often developed
systemic complications (cardiorespiratory failure, sepsis) than those with a higher WBC (53 of 104
[51%] vs. 69 of 216 [32%]; P = 0.001). In a multivariate analysis, advanced age (Odds ratio per 10-
year increments 1.22, 95%CI 1.02–1.45), a positive blood culture (Odds ratio 2.46, 95%CI 1.17–
5.14), and a low thrombocyte count on admission (Odds ratio per 100,000/mm3 increments 0.67,
95% CI 0.47–0.97) were associated with a CSF WBC <1000/mm3.
Conclusion: A low CSF WBC in adults with pneumococcal meningitis is related to the presence
of signs of sepsis and systemic complications. Invasive pneumococcal infections should possibly be
regarded as a continuum from meningitis to sepsis.
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Background
Bacterial meningitis is a life-threatening disease [1,2].
Recently we evaluated clinical features and prognostic fac-
tors in a prospective cohort study of 696 episodes of com-
munity-acquired acute bacterial meningitis [3]. The most
common pathogens were Streptococcus pneumoniae and
Neisseria meningitidis. The mortality rate was 21 percent
and was higher among patients with pneumococcal men-
ingitis than among those with meningococcal meningitis
(30% vs. 7%, P < 0.001). The outcome was unfavourable
in 34 percent of episodes and the strongest risk factors for
an unfavourable outcome were symptoms indicative of
systemic compromise, a low level of consciousness, infec-
tion with S. pneumoniae, and a low cerebrospinal fluid
(CSF) white-blood cell count (WBC). The relation
between unfavourable outcome and a low CSF WBC has
been described previously in both patients with N. menin-
gitidis and S. pneumoniae meningitis [3-6]. In patients with
meningococcal meningitis, a low CSF WBC indicates the
presence of sepsis with early meningitis [3]. The relation
between CSF WBC and outcome in patients with pneu-
mococcal meningitis is not understood [2-4]. A recent
study in experimental pneumococcal meningitis sug-
gested that an attenuated CSF pleocytosis was likely the
result of a decrease in blood WBC induced by bacteraemia
[7]. This suggests that a low CSF WBC in patients with
pneumococcal meningitis may indicate the presence of
sepsis, analogous to meningococcal disease. The aim of
the present study was to examine the relation between
CSF pleocytosis, bacteraemia and sepsis in a prospective
cohort study of adults with pneumococcal meningitis.
Methods
The Dutch Meningitis Cohort Study, a prospective nation-
wide observational cohort study in the Netherlands,
includes 696 episodes of community-acquired bacterial
meningitis [3]. Inclusion and exclusion criteria are
described more extensively elsewhere [3]. In summary,
eligible patients were aged >16 years and had CSF culture
proven bacterial meningitis. CSF culture yielded S. pneu-
moniae in 352 episodes (51%), N. meningitidis in 257 epi-
sodes (37%), and other bacteria in 87 episodes (13%) [3].
The Dutch Meningitis Cohort Study was approved by our
ethics committee and written informed consent was
obtained from participating patients or their legally
authorised representatives. Information was collected by
means of a case record form. Patients using immunosup-
pressive drugs and patients with diabetes mellitus, alco-
holism, asplenia or infection with the human
immunodeficiency virus were considered immunocom-
promised. Fever was defined as a body temperature
≥38°C. A diastolic blood pressure <60 mm Hg was used
as a surrogate marker for septic shock. Patients underwent
a neurological examination at discharge and outcome was
graded by means of the Glasgow Outcome Scale (GOS).
This is a well validated measurement scale with scores var-
ying from 1 (indicating death) to 5 (good recovery) [3,8].
A favourable outcome was defined as a score of 5, and an
unfavourable outcome as a score 1–4.
For nonparametric testing, χ2- or Fisher's exact statistics
were used. Correlation between parameters was per-
formed by non-parametric Spearman rank test. We used
logistic regression analysis to calculate odds ratios and
95% confidence intervals (CI) to assess the strength of the
association between potential factors and a low CSF WBC
(defined as a CSF WBC <1000/mm3). Although the
median percentage of missing values for potential factors
was low (2%), data were complete for all factors in only
175 episodes (50%) [4]. Missing values were imputed by
use of multivariate normal distributions, and the coeffi-
cients of ten rounds of imputation were combined to
obtain the final estimates from the multivariate model
[3,4]. All statistical tests were two-tailed, and we consid-
ered a P value less than 0.05 as statistically significant. All
analyses were undertaken with SAS software (version
9.11).
Results
A total of 352 episodes of pneumococcal meningitis
occurred in 343 patients; 9 patients had a second episode
during the study period. Characteristics of the study pop-
ulation, clinical course and outcome are described more
extensively elsewhere [3,4].
All patients underwent lumbar puncture. CSF WBC was
determined in 320 episodes (91%); median CSF WBC was
2530 per mm3 (interquartile range 531 to 6983 per mm3)
and in 104 of 320 episodes (33%) CSF WBC was <1000/
mm3 (Table 1). Patients with a CSF WBC <1000/mm3
were significantly older than those with a higher CSF WBC
(mean age 62 vs. 57 years; P = 0.01), were less likely to
have complaints <24 hours before admission (39 of 97
[40%] vs. 110 of 200 [55%]; P = 0.02), more often had a
positive blood culture (72 of 84 [86%] vs. 138 of 196
[70%]; P = 0.01) and an immunocompromised status (31
of 104 [30%] vs. 39 of 215 [18%]; P = 0.02). Patients with
a CSF WBC below or above 1000 per mm3 had similar
proportions of patients with fever, tachycardia (heart rate
>120 beats/min) or diastolic blood pressure <60 mmHg
on admission. Although several factors were significantly
associated with a low CSF WBC in the univariate analysis,
most factors were not significant in the multivariate anal-
ysis. In the multivariate model, advanced age (Odds ratio
per 10-year increments 1.22, 95%CI 1.02–1.45), a posi-
tive blood culture (Odds ratio 2.46, 95%CI 1.17–5.14),
and a low thrombocyte count on admission (Odds ratio
per 100,000/mm3 increments 0.67, 95%CI 0.47–0.97)
were significantly associated with a CSF WBC <1000/
mm3.BMC Infectious Diseases 2006, 6:149 http://www.biomedcentral.com/1471-2334/6/149
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To further explore our data we performed an analysis of
correlations between indexes of inflammations in CSF
and blood (Table 2). There was a significant correlation
between CSF and blood WBC (Spearman's test 0.29, P <
0.001). CSF WBC was also significantly associated with
CSF protein level (Spearman's test 0.20, P  = 0.001),
thrombocyte count (0.21, P  < 0.001) and indexes of
inflammation in the blood: erythrocyte sedimentation
rate (ESR, -0.15, P = 0.02), and C-reactive protein level
(CRP, -0.18, P = 0.02). Blood WBC was significantly asso-
ciated with thrombocyte count (Spearman's test 0.35, P <
0.001) and ESR (-0.12, P = 0.04), but not with CRP, CSF
protein or CSF glucose level.
Episodes with a CSF WBC <1000/mm3 were more likely to
develop systemic complications (cardiorespiratory failure
and/or sepsis) during clinical course than those with
higher CSF WBC (53 of 104 [51%] vs. 69 of 216 [32%]; P
Table 2: Correlations between indexes of inflammation in cerebrospinal fluid and blood
CSF WBC CSF glucose level CSF protein level Blood WBC Thrombocyte count ESR CRP
CSF WBC 1.0 0.002 0.20** 0.29** 0.21** -0.15* -0.18*
CSF glucose level 0.002 1.0 -0.37* -0.03 0.13* -0.12 -0.16*
CSF protein level 0.20** -0.37* 1.0 0.10 -0.17** 0.07 0.14
Blood WBC 0.29** -0.03 0.10 1.0 0.35** -0.12* -0.06
Thrombocyte count 0.21** 0.13* -0.17** 0.35** 1.0 0.15* -0.18*
ESR -0.15* -0.12 0.07 -0.12* 0.15* 1.0 0.48**
CRP -0.18* -0.16* 0.14 -0.06 -0.18* 0.48** 1.0
All data are given as Spearman's correlation coefficients.
*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).
CSF, cerebrospinal fluid; WBC, white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Table 1: Multivariate analysis of factors associated a low cerebrospinal fluid leukocyte count*
Characteristics CSF WBC <1000/mm3 
(n = 104)
CSF WBC ≥1000/mm3 
(n = 216)
Odds Ratio (95% CI)† P-value
Mean age ± SD – years 62 ± 17 57 ± 16 1.22 (1.02–1.45) 0.03‡
Duration of symptoms <24 hr 39/97 (40) 110/200 (55) 1.59 (0.93–2.72) 0.09‡
Immunocompromise§ 31 (30) 39/215 (18) 1.74 (0.95–3.18) 0.07‡
Heart rate < 60 beats/min 3/101 (3) 3/202 (1) 3.90 (0.75–20.29) 0.11
Heart rate 60–90 beats/min 26/101 (26) 60/202 (30) - ¶
Heart rate 90–120 beats/min 45/101 (45) 91/202 (45) 1.00 (0.53–1.89) 0.99
Heart rate >120 beats/min 27/101 (27) 48/202 (24) 1.22(0.52–2.90) 0.65
Diastolic blood pressure <60 mmHg 5/103 (5) 12/209 (6) 0.79 (0.23–2.67) 0.70
Body temperature ≥38°C 84/103 (82) 181/212 (85) 0.59 (0.26–1.29) 0.18
Glasgow Coma Scale score$ 11 (8–13) 10 (8–12) 1.08 (0.96–1.20) 0.20
Focal neurologic deficits 47 (45) 93 (43) 1.14 (0.67–1.94) 0.64
CSF protein level – g/L$ 3.9 (2.2–6.3) 4.7 (2.9–7.1) 0.94 (0.85–1.03) 0.18
CSF:blood glucose ratio$ 0.06 (0.01–0.17) 0.05 (0.01–0.23) 1.08 (0.79–1.49) 0.62
Positive blood culture 72/84 (86) 138/196 (70) 2.46 (1.17–5.14) 0.02‡
ESR – mm/hour$ 47 (23–87) 43 (20–71) 1.14 (0.94–1.39) 0.18
Blood WBC <10 – 109/L 22 (21) 16/213 (8) 1.93 (0.90–4.16) 0.09‡
Blood WBC 10–20 – 109/L 51 (49) 109/213 (51) - ¶
Blood WBC ≥20 – 109/L 31 (30) 88/213 (41) 0.91 (0.49–1.68) 0.76‡
Thrombocyte count – platelet/mm3 $ 171,000 (118,000–234,000) 214,000 (175,000–262,000) 0.67 (0.47–0.97) 0.03‡
*Table includes 320 patients in which CSF WBC was determined. Data are given as no. of patients with characteristic/no. evaluated (%) or median 
(interquartile range), unless indicated otherwise.
†odds ratios are calculated in 10-year increments for age, per increments of 0.2 g/L protein, per 20 mm per hour for ESR, and per 100,000/mm3 for 
thrombocyte count.
‡significant association in univariate analysis.
§defined as the use of immuno-suppressive drugs, presence of asplenia, diabetes mellitus, alcoholism or infection with the human immunodeficiency 
virus.
¶this group served as a reference category.
$Glasgow Coma Scale score was obtained in 319 patients, CSF protein level was determined in 300 patients, CSF:blood glucose ratio in 294, ESR in 
256, and the thrombocyte count in 295 patients.
CSF, cerebrospinal fluid; WBC, white blood-cell count; ESR, erythrocyte sedimentation rate.BMC Infectious Diseases 2006, 6:149 http://www.biomedcentral.com/1471-2334/6/149
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= 0.001). The proportion of episodes with neurological
complications (seizures, impairment of consciousness, or
focal neurological abnormalities) was similar in episodes
with a CSF WBC below and above 1000 cells per mm3 (84
of 104 [81%] vs. 158 of 216 [73%], respectively, P = 0.14).
Discussion
Our findings indicate that a low CSF WBC in adults with
pneumococcal meningitis is related to the presence of
signs of sepsis and systemic complications. This is analo-
gous to findings in patients with meningococcal meningi-
tis [3]. Therefore, invasive pneumococcal infections
should possibly also be regarded as a continuum from
meningitis to sepsis, rather than of infections in isolated
systemic and central nervous system compartments.
Leukocyte recruitment is a key aspect of the host response
against invading micro-organisms [2]. In experimental
pneumococcal meningitis blocking of leukocyte accumu-
lation in the CSF augmented bacteraemia and increased
mortality due to severe sepsis [9]. Another study in ani-
mals with pneumococcal meningitis showed a relation
among a large CSF bacterial load, lack of response of CSF
leukocytes and intracranial complications [10]. This sug-
gests that low CSF WBC is related to excessive bacterial
growth. In clinical studies, a low CSF WBC is a strong indi-
vidual predictor of unfavourable outcome [3-5]. A recent
study in experimental pneumococcal meningitis explored
the role of systemic infection on meningeal inflammation
[7]. In this study, meningitis was induced in rabbits by
intracisternal injection of ~1 × 106 colony forming units S.
pneumoniae  type 3; WBC and bacterial concentrations
were regularly determined in blood and CSF [7]. The ani-
mals were either provided with a similar dose of pneumo-
cocci intravenously at 0 hour (bacteraemic rabbits), pre-
treated with paraformaldehyde-killed pneumococci
(immunized rabbits) or not treated further (controls).
Bacteraemic rabbits showed a decrease in blood WBC
between 10–16 hours after inoculation and had an atten-
uated CSF pleocytosis as compared to the other groups
between 12–16 hours from time of infection.
A weak leukocyte response in the CSF was significantly
associated with advanced age. In a previous analysis of the
Dutch Meningitis Cohort study, systemic complications
have been noted as the leading causes of death in elderly
patients with bacterial meningitis [11]. In the present
study we lacked data for analyzing international accepted
criteria of sepsis and septic shock [12]. We used a low
diastolic blood pressure as a surrogate marker, which is a
limitation of our study. Our results show a weak leukocyte
response in the CSF was associated with bacteraemia and
other factors related to systemic compromise; however,
the association with a low blood WBC on admission did
not reach statistical significance in our multivariate
model. Therefore, a direct causal relationship between an
attenuated CSF pleocytosis and a decrease in blood WBC
induced by bacteraemia remains speculative.
A recent randomised, placebo-controlled trial involving
301 adults with suspected meningitis in combination
with cloudy cerebrospinal fluid, bacteria in the CSF on
Gram's staining, or a CSF WBC of more than 1000 per
mm3, showed that adjunctive treatment with dexametha-
sone before or with the first dose of antimicrobial therapy
reduced the risk of unfavourable outcome from 25 per-
cent to 15 percent (number needed to treat, 10 patients)
[13]. In this study, the effect of dexamethasone on out-
come was most striking in patients with pneumococcal
meningitis, in which mortality was decreased from 34 to
14 percent. A post hoc analysis of this study showed that
the beneficial effect of dexamethasone on mortality in
pneumococcal meningitis was attributable to a reduction
in systemic complications, rather than neurological com-
plications [14]. In a categorization of death of patients
with pneumococcal meningitis who died within 14 days
after admission, the percentage of patients who died due
to neurological causes was similar between groups. The
percentage of patients who died due to a systemic cause
was significantly smaller in the dexamethasone group
than in the placebo group (2 vs. 16%; Relative risk 0.11;
95%CI 0.04–0.25). The systemic complications that were
potentially preventable by dexamethasone were pulmo-
nary complications and septic shock [14]. As one of the
inclusion criteria was a CSF WBC of more than 1000 per
mm3, a subgroup analysis of patients included in this
study with low CSF WBC on the effect of dexamethasone
cannot be performed. In the current study, patients did
not routinely receive corticosteroids [3]. This may well
have influenced our results concerning the relation with
development of complications during clinical course.
However, this has not influenced our results on the corre-
lation between CSF WBC, blood WBC and other indexes
of inflammation in the blood since adjunctive dexameth-
asone is generally started after blood and CSF samples are
obtained.
Conclusion
We found a significant correlation between CSF WBC,
blood WBC and other indexes of inflammation in the
blood. In addition, a CSF WBC below 1000 per mm3 was
a risk factor for the development of systemic complica-
tions in patients with pneumococcal meningitis. These
findings suggest that a low CSF WBC may be due the pres-
ence of bacteraemia and sepsis with early meningitis and
invasive pneumococcal infections should possibly be
regarded as a continuum from meningitis to sepsis.Publish with BioMed Central    and   every 
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